Om Megashree Pharmaceuticals Limited has officially closed the subscription period for its Initial Public Offering (IPO) allocated to Nepali citizens working abroad. The IPO, which opened on February 3, 2025, was specifically designed to provide investment opportunities for Nepalese migrant workers and received an overwhelming response.
IPO Subscription Details for Foreign Employment workers
- Total Shares Reserved: 180,000 shares (10% of the total public issue)
- Subscription Period: February 3, 2025 – February 17, 2025
- Minimum Application: 10 shares
- Maximum Application: 10,000 shares
With the subscription period now closed, the company and its issue manager, Prabhu Capital Limited, will proceed with the allotment process in accordance with Nepal’s Securities Board (SEBON) guidelines.
What Happens Next?
- IPO Allotment Process: The allotment will be conducted through a fair lottery system.
- Allotment Date: The official date for the allotment results will be announced soon.
- Crediting of Shares: Successfully allotted shares will be deposited into the respective investors’ Demat accounts.
- Refunds: Unsuccessful applicants will receive their refunds within a few business days.
How to Check IPO Allotment Status?
Investors can check their allotment status once announced through:
- Mero Share Portal (https://meroshare.cdsc.com.np/)
- Prabhu Capital Limited’s Official Website (https://prabhucapital.com/)
- Om Megashree Pharmaceuticals Limited’s Official Website
Market Expectations
Om Megashree Pharmaceuticals Limited is expected to list its shares on NEPSE (Nepal Stock Exchange) soon after the allotment process is completed. The company aims to strengthen Nepal’s pharmaceutical sector by providing high-quality medicines manufactured in Chitwan, Nepal.
For further updates regarding IPO allotment and listing, stay connected with the latest financial news and official announcements from Om Megashree Pharmaceuticals Limited.
For any information related to IPOs and the process of applying for an IPO in Nepal from UAE, please feel free to contact our team.
